Lee, Hae-Young
(Department of Internal Medicine, Seoul National University Hospital)
Chung, Wook-Jin (Department of Internal Medicine, Gachon University Gil Medical Center) Jeon, Hui-Kyung (Department of Internal Medicine, College of Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea) Seo, Hong-Seog (Department of Internal Medicine, Korea University Guro Hospital) Choi, Dong-Ju (Department of Internal Medicine, Seoul National University Bundang Hospital) Jeon, Eun-Seok (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Kim, Jae-Joong (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) Shin, Joon Han (Department of Internal Medicine, Ajou University Hospital) Kang, Seok-Min (Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine) Lim, Sung Cil (Department of Clinical Pharmacy, College of Pharmacy, The Catholic University of Korea) Baek, Sang-Hong (Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea) |
1 | Bruck H, Leineweber K, Temme T, et al. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol 2005;46:2111-2115. DOI |
2 | Rochais F, Vilardaga JP, Nikolaev VO, Bunemann M, Lohse MJ, Engelhardt S. Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest 2007;117:229-235. DOI |
3 | Fiuzat M, Neely ML, Starr AZ, et al. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur J Heart Fail 2013;15:258-266. DOI |
4 | Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003;43:381-411. DOI |
5 | Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy 2007;27:874-887. DOI |
6 | Rienstra M, Damman K, Mulder BA, Van Gelder IC, Mc-Murray JJ, Van Veldhuisen DJ. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail 2013;1:21-28. DOI |
7 | Lee SE, Cho HJ, Lee HY, et al. A multicentre cohort study of acute heart failure syndromes in Korea: rationale, design, and interim observations of the Korean Acute Heart Failure (KorAHF) registry. Eur J Heart Fail 2014;16:700-708. DOI |
8 | Youn JC, Seo SM, Lee HS, et al. Trends in hospitalized acute myocardial infarction patients with heart failure in Korea at 1998 and 2008. J Korean Med Sci 2014;29:544-549. |
9 | Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002;347:1135-1142. DOI |
10 | Borjesson M, Magnusson Y, Hjalmarson A, Andersson B. A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000;21:1853-1858. DOI |
11 | Forleo C, Resta N, Sorrentino S, et al. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 2004;117:451-458. DOI |
12 | Biolo A, Salvaro R, Clausell N, Silvello D, Santos KG, Rohde LE. Impact of beta-2 Thr164Ile and combined beta- adrenergic receptor polymorphisms on prognosis in a cohort of heart failure outpatients. Braz J Med Biol Res 2010;43:565-571. DOI |
13 | Yogev D, Basheer M, Blotnick S, Caraco Y, Muszkat M. Effects of sex and the common ADRB1 389 genetic polymorphism on the hemodynamic response to dobutamine. Pharmacogenet Genomics 2015;25:555-563. |
14 | Cullington D, Goode KM, Clark AL, Cleland JG. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? Eur J Heart Fail 2012;14:737-747. DOI |
15 | Greene SJ, Vaduganathan M, Wilcox JE, et al. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. JACC Heart Fail 2013;1:488-496. DOI |
16 | White HL, de Boer RA, Maqbool A, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 2003;5:463-468. DOI |
17 | Wagoner LE, Craft LL, Zengel P, et al. Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J 2002;144:840-846. DOI |
18 | Terra SG, Pauly DF, Lee CR, et al. Beta-adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 2005;77:127-137. DOI |
19 | Chen L, Meyers D, Javorsky G, et al. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics 2007;17:941-949. DOI |
20 | Metra M, Covolo L, Pezzali N, et al. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther 2010;24:49-60. DOI |
21 | Lee HY, Cho HJ, Kim HY, et al. Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study. Korean J Intern Med 2014;29:754-763. DOI |
22 | Biolo A, Clausell N, Santos KG, et al. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol 2008;102:726-732. DOI |
23 | Mahesh Kumar KN, Ramu P, Rajan S, Shewade DG, Balachander J, Adithan C. Genetic polymorphisms of beta1 adrenergic receptor and their influence on the cardiovascular responses to metoprolol in a South Indian population. J Cardiovasc Pharmacol 2008;52:459-466. DOI |
24 | Wood AJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991;20:350-373. DOI |
25 | Muszkat M. Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9. Clin Pharmacol Ther 2007;82:215-218. DOI |
26 | Ogimoto A, Okayama H, Nagai T, et al. Impact of synergistic polymorphisms in adrenergic receptor-related genes and cardiovascular events in patients with dilated cardiomyopathy. Circ J 2012;76:2003-2008. DOI |
27 | Brodde OE. Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol Ther 2008;117:1-29. DOI |
28 | Azuma J, Nonen S. Chronic heart failure: beta-blockers and pharmacogenetics. Eur J Clin Pharmacol 2009;65:3-17. DOI |
29 | Cappola TP, Dorn GW 2nd. Clinical considerations of heritable factors in common heart failure. Circ Cardiovasc Genet 2011;4:701-709. DOI |
30 | Cresci S, Kelly RJ, Cappola TP, et al. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol 2009;54:432-444. DOI |
31 | Filigheddu F. Genetic prediction of heart failure incidence, prognosis and beta-blocker response. Mol Diagn Ther 2013;17:205-219. DOI |
32 | Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006;103:11288-11293. DOI |
33 | Liggett SB, Tepe NM, Lorenz JN, et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 2000;101:1707-1714. DOI |
34 | Petersen M, Andersen JT, Hjelvang BR, et al. Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. Br J Clin Pharmacol 2011;71:556-565. DOI |
35 | Liu WN, Fu KL, Gao HY, et al. beta1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to beta-blocker therapy and prognosis. PLoS One 2012;7:e37659. DOI |
36 | Liu J, Liu ZQ, Yu BN, et al. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 2006;80:23-32. DOI |
37 | Terra SG, Hamilton KK, Pauly DF, et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 2005;15:227-234. DOI |
38 | O'Connor CM, Fiuzat M, Carson PE, et al. Combinatorial pharmacogenetic interactions of bucindolol and beta1, alpha2C adrenergic receptor polymorphisms. PLoS One 2012;7:e44324. DOI |
39 | Mesangeau D, Laude D, Elghozi JL. Early detection of cardiovascular autonomic neuropathy in diabetic pigs using blood pressure and heart rate variability. Cardiovasc Res 2000;45:889-899. DOI |
![]() |